Accro Bioscience

Suzhou, China · Founded 2017 · Privately Held (backing)

Developer of small molecule innovative drugs designed for inflammatory, autoimmune diseases and cancer. Accro Bioscience is based in Suzhou, China and was founded in 2017. Its last reported valuation was $161 million in Jan 2022. It has raised $62 million.

Last reported valuation

$161.0M

Oct 2026

Priced at

—

Total raised

$62.0M

Last round

—

How much has Accro Bioscience raised?

$62.0Macross 0 recorded rounds

Free account

More of Accro Bioscience with a free account

·Watch Accro Bioscience: the Monday email on marks, rounds and moves

Create free account

No card required

Membership and data by Private Market View

Accro Bioscience investors

10 investors are on record for Accro Bioscience, including Suzhou Oriza Holdings Corporation, Shenzhen Capital Group, Hefei Innovation Technology Venture Capital and 5Y Capital. By type, the record holds 4 venture capital firms and 1 asset manager.

For fundraisers

Raising for a company like Accro Bioscience?

10 investors have backed Accro Bioscience.

See all 10 investors →

Frequently asked about Accro Bioscience

How much has Accro Bioscience raised?: Accro Bioscience has raised $62.0M in total across 0 recorded funding rounds.